NYSE:PFE

Pfizer Inc (PFE)

25.71
+0.37 (1.46%)
as of Jun 4, 2026, 6:38:50 pm Market Open.
579 watching
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY
Top quality company. Cheap. Good sector for the long term.
BUY
Sector has been hit hard. A very liquid stock.
DON'T BUY
Governments are trying to cut health care costs. Sector seems to be weak.
BUY
US pharmaceutical sector is very cheap now.
TOP PICK
Trading at less than 20 X earnings. Reasonable dividend yield. Have some new products in the pipeline.
BUY
Looks good.
TOP PICK
Likes the valuations. Good balance sheet and good earnings. Made some good acquisitions.
HOLD
Fair market value is more than share price.
BUY
Now is a good time for drug stocks.
BUY
At a good level now.
BUY
Earnings growth is sustainable.
BUY
In the midst of a large merger.
BUY
Extremely cheap. Great product line up.
WEAK BUY
Starting to look good at $26.
DON'T BUY
Great company. Could drop further.
Showing 796 to 810 of 883 entries